Podcasts about Monty

The Germans attack before the Allies can start up again. Then the rains come in earnest. Tunis is safe for now, but Rommel in the south is losing against Monty and his own Allies. Learn more about your ad choices. Visit megaphone.fm/adchoices

The guys mix up an equal-parts sipper from 2015, short for "Monty y Mezcal."M AND M RECIPE:1 part MEZCAL 1 part AMARO MONTENEGRO Stir ingredients on ice and strain into an ice-filled rocks glass.Express orange or lime peel over the cocktail and use as garnish.Recipe via Difford's Guide Hosted on Acast. See acast.com/privacy for more information.

We start today with some awfully sad news, long time wolfpackers would know our rules guy Stu McPhee, whenever we needed anything clarified, Stu was our go to guy - what he didn't know wasn't worth knowing. Sadly, Stu passed away last week from cancer, and we acknowledge him on the pod today, and our thoughts are with his family at such a difficult time.And then, as Stu would have expected, we get on with the show.Michael had a question about bag maintenance on course, and who drives that - player or caddy - Nick and Mark explain their approaches. Nick tells a great story about playing in the Australian Open without any wet weather guy....was he focused and tough? Or did he just forget to pack wet weather gear? We find out.Question from 'anonymous' on two friends of his who are going to Cypress Point and the Ryder Cup shortly. Anon has two questions, one for Nick and one for Mark. Leads to a chat about AFL theme songs, for international wolfpackers, AFL football clubs in Australia have theme songs and Nicks favourite team has the definitive worst theme song of all.After the turn, a Vietnam update, Nick is there for the week, we find out where he's played since the earlier pod, and where he's playing today. We get some Monty comments - always fun. And then an amazing story from a wolfpacker about crocodiles at Royal Port Moresby Golf Club !!!!!And we wrap with a question from Dean about pace of play, a hot button for Nick and Mark.We're live from Titleist and FootJoy HQ thanks to our great partners:BMW, luxury and comfort for the 19th hole;Titleist, the #1 ball in golf;FootJoy, the #1 shoe and glove in golf;PING will help you play your best;Golf Clearance Outlet, they beat everyone's prices;Betr, the fastest and easiest betting app in Australia;And watchMynumbers and Southern Golf Club. Hosted on Acast. See acast.com/privacy for more information.

THE WES BUCK SHOW – EPISODE 399“QUEEN OF INDY, KINGS OF THE BULLET”SHE HIT 50 WINS.HE TOOK HOME PRO MOD GOLD.AND A PROMOTER WHO STARTED A MOVEMENT IS HERE TO TELL THE TALE.This week on The Wes Buck Show, we're celebrating drag racing greatness on every level.First up, the Queen of Pro Stock, Erica Enders, joins us after her massive win at the NHRA U.S. Nationals in Indy. This was her 50th career national event win, and yeah, she's only the second professional drag racer in history to do it behind John Force. All-time legend. All-time closer. You do not want to line up next to her when it counts.Then, back by popular demand, Steve King checks in after taking the Pro Mod win at the Yellow Bullet Nationals. He's on an absolute tear, one of the hottest drivers in the game right now, and doing more than his fair share to grow the sport while he's at it.And to round it out, we've got the man behind the madness himself — Monty Mikho. The promoter, the originator, the dude who launched the Yellow Bullet Nationals and helped turn it into one of the most beloved outlaw races in the country. He's got stories, perspective, and probably a couple things to say that'll fire people up.It's big wins. Big personalities. Big vibes.Wes Buck, JT “Murder T” Hudson, and Mike Carpenter are ready to throw down with the best of the best.DON'T MISS IT. LET'S GOOOOO.⸻Each week on The Wes Buck Show, Wes Buck, JT “Murder T” Hudson, and Mike Carpenter bring their unique insights and analysis to the most electrifying moments and storylines from a packed weekend of drag racing.

ATTACHMENT STYLES. In this episode of the Came to Believe Recovery Podcast, Tom, Alicea and Monty discuss the four Attachment Styles most common with people. Are these healthy? Can they be useful? Where are you in these descriptions? How does recovery play a part in these styles?#recovery #alcoholic #twelvesteps #wedorecover #addiction 

This week, Mel's fact reminds Monty of a terrifying event that recently happened in her home, that ended with a major PPM (Proud Parenting Moment). There’s also the Aussie singer’s son with incredible pipes and Mel’s MUCH less impressive childhood performances. Monty’s son’s school is evacuated for a scary - but vintage - reason, Mel is reminded of an 80’s ad with a very adult moment, and we disagree over whether sucking a dummy as a form of self-regulation beyond the toddler years is ok. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

Cal and Monty are joined by Ewan Paton from the Killie Chronicle as we lookahead to Sunday's game against Celtic.

Dom talks with Monty White, Agricom's Eastern North Island Territory Manager and Industry Support, about returning to Central Hawke's Bay, his time working in the UK and his lifelong interest in agronomy. Tune in daily for the latest and greatest REX rural content on your favourite streaming platform, visit rexonline.co.nz and follow us on Instagram, Facebook and LinkedIn for more.

Week 1 in the NFL ends with incredible Sunday night game as Bills rally past Ravens! Rivals break down everything you need in Week 1, share our new top 5 and give you our picks for next week! Week 1 saw Monty go 2-0 and Ernie have tough luck in going 0-2! Plus, Hawaii wins! Letʻs get after it!

Sermon Notes Date: 09/07/2025 Preacher: Josh Peglow, pastor Series: Colossians Key Text: Colossians 2:16-23 Description: It's tempting to think that adding more makes things better… but sometimes adding only leads to loss. Today on Scandia Bible Church Podcast, Pastor Josh Peglow continues our study in the book of Colossians, where Paul warns us against the […]

Week 1 in the NFL ends with incredible Sunday night game as Bills rally past Ravens! Rivals break down everything you need in Week 1, share our new top 5 and give you our picks for next week! Week 1 saw Monty go 2-0 and Ernie have tough luck in going 0-2!  Plus, Hawaii wins!  Letʻs get after it!

Episode 574! It's WWE Clash in Paris! James, Jaxie, Monty and Gina are here! We review all things WWE! With the European tour and a HUGE return we have plenty to talk about! Plus lot's more! Enjoy!!

Did you meet JACKSON on Friday's show? Would be cool if you did It's SUNDAY so JACKSON goes on the journey with TALOR and MATTY into the MAILBAG to help with some start/sit decisions before the almighty return of STARTS of the WEEK.This year the stakes are higher with some new rules and a new scoring function. How will the fellas react and who will they recommend as worthy starters this week from players who are in less than 50% of starting line ups on SLEEPER?Get yoursef a SONIC & KNUCKLES shirt to cheer on Gibbs and Monty this year at our merch store: https://linktr.ee/AussieGridironNetwork

See omnystudio.com/listener for privacy information.

Most firms chase more leads. Monty Cain squeezed more cases out of the leads he already had. By treating law like customer service, retooling intake, and training his team to spot mild TBI patterns, he uncovered value hiding in plain sight. On trucking files, he goes past the driver to expose carrier‑level failures—and he helped cement the right to bring those claims in Oklahoma courts. The result: more signed cases, stronger case value, and referrals that snowball. You'll learn: The intake shift that increased signed cases ~25% without extra ad spend. How asking better questions surfaces mild TBI in 15–20% of crash cases—and what to do next. Turning client experience into a marketing channel (reviews, returns, and referrals). If you like what you hear, hit subscribe. We do this every week. VIP PIMCON Tickets:  Pimcon.org Get Social! Personal Injury Mastermind (PIM) is on Instagram | YouTube | TikTok

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Matt Haugen Monty's Plant Food - Crop Update

VANITY, VANITY. In this episode of the Came to Believe Recovery Podcast, Monty, Alicia, and Tom explore the themes of recovery, vanity, and self-acceptance. They celebrate Monty's sobriety milestone and engage with listener mail discussing the balance between recovery promises and personal growth. The conversation delves into the societal pressures surrounding beauty and the implications of plastic surgery, while also reflecting on the importance of accountability in recovery. Ultimately, the hosts encourage listeners to embrace their authentic selves and consider the deeper motivations behind their desires for change. Closing Song: Higher Power by Conley White  #recovery #alcoholic #twelvesteps #wedorecover #addiction  

** Latest Sept 2nd Pod : Reloaded  & renamed after naming error **Desi is joined by Hector, Monty and Karen (@HappyCelticLass on Twitter) to talk about the Weirdest Week ever for Celtic Football Club,The talk about how everything that could go wrong DID go wrong and they wonder just who if any WASNT at fault!They discuss the Champions League exit, The Hun no show draw and the absymal transfer Window.They wonder just what is next and consider certain peoples futures!.On a brighter note, they got to celebrate the Celtic Womens Team doing well so far this season

 A fair amount of cutting back and pruning takes places at Longmeadow. Monty Don explains when it all happens and why, and clarifies when plants should be cut back and when to leave them. Along with making sure you have the correct tool for the job, he also discusses the importance of using the right gardening kit and techniques - and reassures that if mistakes are made, the plant will probably recover quicker than you think. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This month, we're diving into chapter three from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio!Horsemanship Radio 286:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Episode Notes The Not-Quite-Northern-Lights come to the international waters just outside of Danville. Monty reconnects with Vanessa. Doof and Perry get tiny. Then, the Fireside Girls devolve into chaos. Meanwhile, the search for the Claire's Diamond continues. Email us at: CandacePartyPodcast@gmail.com TikTok: @CandacePartyPodcast Instagram: @CandacePartyPod Well, back to my closet!

Sermon Notes Date: 08/31/2025 Preacher: Monty Simao, pastor Series: Zechariah Key Text: Zechariah 13:7-9 Description: What kind of love leads a Shepherd to take the sword? …even for sheep He knows will scatter? Today on Scandia Bible Church Podcast, Pastor Monty Simao continues in the book of Zechariah, where we see God summon the sword […]

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

This week, Where's That Bar Cart reaches a new frontier. Darryl got to be a Marshall AND a Bart Cart Boy AT THE SAME TIME! We break down these worlds colliding. Nick ties his personal best, and Monty announces the first ever annual Where's That Bar Cart Invitational Classic Open Tournament. It is ajar.Thanks to Comedy Records and to each and every one of you who listens, watches, and supports our podcast. Please subscribe to our YouTube channel @ComedyRecords. Swing well out there everyone. Follow us at:- @wheresthatbarcart- linkt.ree/wheresthatbarcart- @dpurcomic- @montymofoscott- @nickdurie- @comedyrecordsMusic by Devin BatesonThank you to Comedy Records

Episode 573! It's AEW Forbidden Door! James, Jaxie, Monty and Gina are all here for all things AEW! We review the event and get a first hand account of being there! Plus lot's more! Enjoy!!

This week, Mel kicks us off with a truly excellent fact that blew our socks off, then we get into a bit of childhood nostalgia with a heavy Royal Melbourne Show theme. We also talk showering (together), baths, Monty tells us about her partner Sam's 'NSB' dinner and we have a cackle over some embarrassing for no reasons. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here. See omnystudio.com/listener for privacy information.

Discover what goes on behind the TV scenes with Monty Don as he talks to Nicki Chapman at BBC Gardeners' World Live in June 2025. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode, Monty answers Listener Questions…tells you what it's like to have a kidney stone…and gives an update on the new Galactic Cowboys album. Plus…What's On TV?!

What a weekend! None of us have gotten as much sleep as we'd like with the Tour Championship on, but Tommy Fleetwood....what a star, and the entire golf world was celebrating his first win. Wonderful. Mark describes the final couple of holes as Tommy playing for his life, as he's not sure how another capitulation would have impacted him. As impressive as the win was, and as consistent as Tommy has been, Mark makes the point that - as with Jon Rahm and LIV last week, he doesn't believe that Tommy should be the Tour Champion, as Scheffler as 'without any shadow of a doubt' been the best player this year. Mark says both LIV and the PGA have this wrong. Nick and Mark discuss options to make it fairer.The new boss of the PGA has been talking about his plans, and one word in his comments has jumped out to Mark, he explains why and we discuss.The Ryder Cup selections will be this week for the US and Keegan Bradley has a big decision to make. Nick and Mark both have a view on what he should do, and explain why.This weekend Mark is playing Royal Melbourne, and he's hoping he is welcomed given his recent comments about the preparedness of the course for the Australian Open, however he is cheering for it to look incredible come December.Our new segment for BMW is a Touch of Class, and this week Nick O'Hern inducts Tommy Fleetwood as our inductee, not for his play, but for his press conference afterwards. We listen to what he said. It was indeed a touch of class from Tommy.Mark has bought something on Temu. Apologies. We tried to stop him but he was determined to show off this $3.50 purchase.After the turn Nick lists the Top 5 'Chokers' in golf......or does he? Top 5 for Betr, and as much as we loved Tommy winning he was responsible for our Betr multi failing so we're a bit dark on him at the same time.Lots of feedback for Southern Golf Club. Feedback on Rahm's title, some good news for Mark re: Monty, a whack for Nick and Mark from Billy, and a whack for Dan from Johnno. Brutal.Hardly know where to start with the PING global results, there has been some massive results - Tommy the big one, but an 'oh so close' result for Minjee in Canada, and plenty of other results to run through.And for watchMynumbers Marks masterclass today, inspired by Patrick Cantlay, is on the importance of having your weight in the right spot.We're live from Titleist and FootJoy HQ thanks to our great partners:Titleist, the #1 ball in golf;FootJoy, the #1 shoe and glove in golf;PING will help you play your best. See your local golf shop or professional for a PING club fitting;Golf Clearance Outlet, visit them online here to find your nearest store.Betr, the fastest and easiest betting app in Australia.And watchMynumbers: download from the App Store or Google Play, and Southern Golf Club: with their brand new Simulator Room. Hosted on Acast. See acast.com/privacy for more information.

Sermon Notes Date: 08/24/2025 Preacher: Monty Simao, pastor Series: Zechariah Key Text: Zechariah 13:1-6 Description: Grace. What if this very thing the Lord uses to forgive… is the same thing He uses to transform? Today on Scandia Bible Church Podcast, Pastor Monty Simao continues in our study of the book of Zechariah — where we […]

Episode 572! It's WWE Summerslam! James, Jaxie, Gina and Monty have so much WWE to catch up on! We have two nights of Summerslam! Raw and Smackdown notes! Plus lot's more! Enjoy!!

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

Monty sits down with the new head baseball coach for the Georgia Tech Yellow Jackets, James Ramsey!

Late summer bridges the lushness of summer and the early signs of autumn. Plants have grown and filled out, the borders are bursting and the garden is relaxed and full-grown. Monty Don discusses his flower borders at Longmeadow and how the Jewel Garden was created. Recorded live at BBC Gardeners' World Live in June. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Sumanta (Monty) Pal and Dr. Arielle Elkrief discuss the clinical relevance of the gut microbiome in cancer immunotherapy and the importance of antibiotic stewardship, as well as interventions currently being explored to treat gut dysbiosis and optimize immunotherapy response. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hi everyone, I'm Dr. Monty Pal, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist. I'm a professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  Today we're here to discuss one of my favorite topics, which is the gut microbiome. It's almost hard to avoid the gut microbiome nowadays if you look at medical literature within oncology. It's an emerging phenomenon, but there are a couple of individuals that I would really define as pioneers in the field. And one of them is actually with me today, Dr. Arielle Elkrief, to discuss the clinical relevance of the gut microbiome, particularly amongst patients receiving immunotherapy, although I imagine our conversation today will take many twists and turns. Arielle is an assistant professor and clinician scientist in the Department of Oncology at the University of Montreal, and she is co-director of the CHUM Microbiome Center there.  FYI for the listeners, we have our full disclosures in the transcript of this episode.  Arielle, thank you so much for joining us today. Dr. Arielle Elkrief: Thanks so much, Monty. This is going to be amazing. Dr. Sumanta (Monty) Pal: Well, I have to tell you what sort of inspired me to bring you on as a guest. It was one of many things, but it was this really terrific ASCO Educational [Book] article that you wrote. Now, I have to tell you, I've read all the articles sort of cover to cover in the book, and they're always a wonderful primer, so if our audience is studying for board research or something of that sort, it's a terrific resource to go through. I have to tell you, this piece on the gut microbiome that you wrote is nothing short of a masterpiece. If you read this cover to cover, it's actually going to give you, I think, a sense of the current state and future state of the field. I wanted to start by just sort of beginning with sort of the origin story for a lot of this, which is this association between the gut microbiome and immunotherapy response. This takes us back several years to this pivotal series of papers in Science. Maybe you could walk our audience through that. Dr. Arielle Elkrief: Absolutely. Well, thank you so much for your kind words about the ASCO [Educational] Book. It was a team effort with a lot of key opinion leaders in the field, so I'm really glad to learn that you've liked it.  Moving backwards in terms of how we came to understand that the gut microbiome is essential to priming a response to cancer immunotherapy actually goes back to 2015 and seminal papers that looked at what happens when we take mice that are germ-free mice that have never been exposed to a microbiome. These are mice that are born by cesarean section and essentially live in a bubble. And when we give those mice tumors and treat them, in the first papers with anti-CTLA-4 treatment, we realized that these antibodies don't work at all. And that was the first observation that the presence of a gut microbiome was essential to mounting an anti-cancer immune response. When we supplemented those same mice with beneficial bacteria or feces from responder patients, we were able to restore the response to immunotherapy. And so those were really the first preclinical observations that made us understand the critical role of the microbiome in immunotherapy response. Moving a little bit in the future, we examined the fecal microbiome composition using shotgun metagenomic sequencing in different cohorts of patients with solid tumors, namely lung cancers, kidney cancers, and also skin tumors like melanoma, and found that patients who responded to immunotherapy had a distinct microbiome that was characterized by beneficial bacteria compared to patients who experienced resistance to immunotherapy that had a dysbiotic or diseased microbiome. Dr. Sumanta (Monty) Pal: So, you know, it's interesting, these techniques that we're using to sequence the gut, they're a little bit different. So I wonder if you can give the audience a quick primer on these techniques that you're so well versed in, shotgun metagenomic sequencing, 16S rRNA sequencing. If you had to describe this in 30 seconds, which is a tall task, how would you do that? Dr. Arielle Elkrief: That's a tall task. Much of what we know about the microbiome initially came from a technique called 16S rRNA sequencing. This is a technique that amplifies the 16S region and basically tells you at the genus level what's going on at the level of bacterial composition. This technique is fast, relatively cheap, and can be performed on a laptop computer, which is excellent. The problem is that it's prone to a lot of technical variations. Different primers might give you different results, and you're really limited at the genus resolution. You can't get a good resolution in terms of species, and we're learning that different species from the same genus might have different physiological properties, and the same thing goes at the strain level. So when we really zone in and look at inter-species changes, we're seeing that these actually have specific functions in the host. So that brings us to metagenomic sequencing, which is a whole genome sequencing, next-generation sequencing based method that looks at the whole composition and gives you information not only on bacteria, but you might also get fungal and viral properties. You can zoom in on the strain level. You can also get functional output, so we can examine what the metabolic properties of specific species or strains might look like. The negative aspects of shotgun metagenomic sequencing is that it takes a lot of computational power in order to analyze the results and it might take a little bit longer. And certainly, within the clinical setting, not something that's feasible yet.  And that brings us to more novel point-of-care biomarker tools that we've collaborated in developing along with Dr. Laurence Zitvogel and Dr. Lisa Derosa at Gustave Roussy, that learning from the shotgun metagenomics results designed a probe using quantitative PCR which looks for this specific bacteria we know to be important and developed a ratio of harmful bacteria to beneficial bacteria. This is called the TOPOSCORE, and it actually is able to predict quite nicely the response to immunotherapy using a stool sample and a really good turnaround time of almost 72 hours. Dr. Sumanta (Monty) Pal: That was a perfect overview and a lot of information in a short amount of time. It also makes you take out your high school biology textbooks, doesn't it, to understand that the bacterial ribosome, right, is a different size and shape, and that's what we're sequencing here. But these techniques I think are incredibly important, and I'm glad you actually discussed this, this RT-PCR based strategy of calculating the TOPOSCORE. It lends itself to this phenomenon of dysbiosis, and I think for our audience, that's going to be an important term to understand as time goes on. There's the normal healthy gut and then there's this phenomenon of dysbiosis, which is, I guess, simply put, an unhealthy gut. But tell us about, you know, how often you see dysbiosis in a cancer patient, maybe versus a normal healthy adult. Dr. Arielle Elkrief: So, I think we can split up your question into two parts. One is we know from cohort studies and population level-based studies that the microbiome of patients with cancer is distinct from healthy patients or healthy people. And we know that because of the global composition. We also think that there are diversity metrics that lend themselves to being described as dysbiotic. But we do know that the microbiome of people with cancer is distinct from healthy volunteers. That's the first point.  In terms of how frequently dysbiosis occurs in patients with cancer, it's not very well defined. We know that even among healthy people, there is a certain level of dysbiosis. Laurence in her talk mentioned that to be about 10% to 20%. And the other fascinating component is that when we're thinking about dysbiosis and the cancer associated microbiome, in terms of the species that are enriched, it's quite striking that a lot of these dysbiotic or negative bacteria are also found to be enriched in patients with metabolic disease, like cardiovascular disease, for example. And so it's unclear if dysbiosis is the cause or consequence, but there definitely seems to be a general pattern of disease when looking at the microbiome compared to healthy people. Dr. Sumanta (Monty) Pal: That's interesting. So, I'll tell you, my second favorite portion of your article, and I'll tell you my favorite portion as well in the context of this podcast, but my second favorite part was the section around antibiotic stewardship. You know, the utilization of antibiotics in a very pragmatic fashion amongst our patients. Can you describe why that's so critical in the context of the microbiome? Dr. Arielle Elkrief: Antibiotics can disrupt the gut microbiome composition. We know this from mouse studies, but also cohort studies of patients that are exposed to antibiotics. And most importantly, we know that patients who are exposed to antibiotics, either before or during the immunotherapy period, have significantly worse progression-free survival and overall survival to immunotherapy. And this is true for immunotherapy in the monotherapy setting, but also when combined with chemotherapy. What's striking is that when we look at patients who are just treated with chemotherapy, we don't see the negative outcome of antibiotics on outcome and progression-free survival and overall survival, suggesting that the negative impact of antibiotics on outcomes is really specific to immunotherapy backbones. The other important point is that this negative signal is maintained even after adjusting for standard prognostic variables in the specific malignancies that we're looking at. And then most importantly, at the mechanistic level, we were able to actually pinpoint the mechanism behind this antibiotic related dysbiosis. And we see this with a bloom of negative bacteria which induces a loss of MAd-CAM, which is an endothelial gut checkpoint immune marker, and that causes an efflux of immunosuppressive T cells, which are usually in the gut, to go straight into the tumor where they make the tumor unamenable to an immunotherapy response. And so now we finally have the mechanism as to why antibiotics are harmful and why we need to practice antibiotic stewardship. Dr. Sumanta (Monty) Pal: And just to be clear for the audience, I mean, if a patient needs antibiotics, they need antibiotics. But perhaps it just suggests that, and we have, I suppose, this predilection as oncologists, just for the minor cold or cough or what have you, we maybe should be a little bit more cognizant of whether or not antibiotics are truly necessary. Is that fair? Dr. Arielle Elkrief: Absolutely. So what we're advocating for is antibiotic stewardship, and this is the clear recommendation that we can make. So that means confirming a bacterial infection. If it's there and antibiotics are indicated, to choose the most narrow spectrum for the shortest course and constantly re-evaluate the indication of antibiotics. And of course, we need to work with our colleagues in infectious diseases who've done incredible work in antibiotic stewardship. And all along this process we also need to be mindful of other medications and polypharmacy, such as proton pump inhibitors or narcotics, for example, we think that these other medications which are frequently prescribed in our cancer population can also potentially have negative impacts on the microbiome and immunotherapy response. Dr. Sumanta (Monty) Pal: I think that's a terrific summary and big guidance for the audience.  I promised you I'd tell you my favorite part of your article, and this is this huge table. I think the table is two and a half pages long, if I remember correctly, but it's an awesome table, and I highly recommend our audience to check this out. It lists literally every therapeutic trial for the microbiome under the sun. And so it begins with the approach of fecal microbiota transplant, which I'm going to ask you to tell us about in a second, but it also hinges on a lot of really cool sort of novel therapies, live bacterial products, mixes of different microbial products. Maybe take us through this whole approach of FMT (fecal microbiota transplantation). I actually wasn't aware of the dozens of trials that you listed there in this space. It seems like it's a very active area of research. Dr. Arielle Elkrief: Definitely. So, as you alluded to, FMT or fecal microbiota transplantation is the most well studied and direct way to modify the patient's microbiome. This technique aims to replace the patient's dysbiotic microbiome with that of a healthy microbiome, either from a healthy donor volunteer that's been heavily screened, or from a patient who experienced response to immunotherapy. And, as three landmark studies so far that have been published demonstrated the potential of FMT to reduce primary resistance or secondary resistance to immunotherapy, and this has been in melanoma.  We also recently reported on the results of our FMT-LUMINate trial, which looked at patients with lung cancer and melanoma. Once again, FMT, when combined with immunotherapy was safe and led to a higher proportion of responses than we would normally expect.  We're now also looking at randomized trials that have come out. So the first being the TACITO trial in kidney cancer, which compared FMT plus pembrolizumab and axitinib to placebo in patients with RCC, and again, FMT was safe and feasible and also led to an increased progression-free survival at one year, meeting the study's primary endpoint.  And so, so far, there's a wealth of data really showing the promise of FMT when combined with immunotherapy, and we're now in the process of conducting larger randomized trials, including in melanoma with the CCTG (Canada Cancer Trials Group) in our ME17 or Canbiome2 trial, where we're going to be enrolling 128 patients with metastatic melanoma to receive FMT and standard of care immunotherapy compared to standard of care immunotherapy alone. Dr. Sumanta (Monty) Pal: You're very humble, so I've got to highlight for our audience. This was a mega grant that Arielle received to fund really the largest prospective exploration of FMT that will exist to date. So I'm really excited about that. I wish this was something we could participate in stateside.  Before we jump into the other approach, which is live bacterial products and mixes thereof, where do you see FMT going? I think that one of the perceived challenges with FMT is that it's hard to implement, right? You need to have a really robust framework when it comes to gastroenterology, the preparation's challenging. Is there a way to envision FMT use being more generalized? Dr. Arielle Elkrief: Those are great questions. So we're lucky in Canada to work with pioneers in FMT, Michael Silverman, Saman Maleki, and John Lenehan in London, Ontario, who had this really robust FMT healthy donor screening program, which literally screens for every pathogen under the sun, and we haven't had any problems with feasibility or implementing FMT in Canada. But I think that once we're going to hopefully start doing larger scale, randomized phase three studies, that we might run into problems with scalability. And I think also with regards to reproducibility, and that's the feedback that we're getting from some regulatory authorities, especially at the level of the FDA, where there are some concerns around inter- and intra-donor variability because, of course, we can't guarantee that every fecal sample is going to be the same. So that has really pushed the field to think about other strategies, such as live biotherapeutic products which take modified FMT or bacteria from stools from either healthy donors or from responder patients and basically turn them into drugs that are regulated as drugs and can then be studied in the context of investigational new drugs or products. Dr. Sumanta (Monty) Pal: I like this and, you know, I do think that there's a future for it. We just have to kind of put our heads together and figure out how to get over all of these logistical hurdles, but, you know, I agree, I think your group and others have demonstrated, especially with this trial that you're fanning out all throughout Canada, that it can potentially be done.  This is a topic that could probably go on for another couple of hours, right, especially based on the size of the table that you put together in this brilliant article, but tell us about live bacterial products or LBPs, as we call them these days. What's the current status, what's the future there? And maybe I'll give you less than two minutes here, although again, I realize it's a two-hour topic. Dr. Arielle Elkrief: You're probably better suited to speak about that because you've been one of the pioneers in terms of this. So we can think about LBPs in terms of single strain organisms, like CBM588 for an example, which your group did some amazing work in showing that, in a randomized setting, that this led to better responses than we would expect compared to just work with controls. We also know that LBPs can have multiple strains, up to 30. We're collaborating with a company called Cannabis Bioscience that is actually working on much larger communities of consortia. And so we're really excited about the direction that that's taking in terms of taking these LBPs and developing them from the drug perspective. In addition to LBPs, we know that there are other ways that we can change the microbiome, notably prebiotics, which are compounds which can have a beneficial impact on the microbiome. And one of these is camu camu, which I know your group is leading a clinical trial looking at camu camu and kidney cancer, and we're excited to see how that compares to FMT or LBPs, because that might be a potentially scalable alternative. Dr. Sumanta (Monty) Pal: That's awesome. What a terrific overview, and that was less than two minutes. I don't know how you did it. That's terrific.  Arielle, this has been such an insightful conversation. I just want to thank you for, again, a terrific article in the ASCO Educational Book. I highly recommend all of our listeners to go there and check it out, and also for sharing all these terrific insights on the podcast today. Dr. Arielle Elkrief: Thank you so much, Monty. Dr. Sumanta (Monty) Pal: And thanks to our listeners, too. If you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal Dr. Arielle Elkrief Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Arielle Elkrief: Honoraria: AstraZenica, Bristol-Myers Squibb, Merck, EMD Serono Consulting or Advisory Role: Bristol-Myers Squibb Research Funding (Inst.): Kanvas Bioscience, AstraZeneca, Merck Other Relationship: Royal College of Surgeons and Physicians of Canada, Cedar's Cancer Center (Henry R. Shibata Fellowship), Canadian Institutes of Health Research (CIHR)

Gerianne Pérez joins us for a candid and hilarious conversation about her winding path from choir kid to Broadway scene-stealer. She shares how an early love of a cappella shaped her artistry, why walking away from a “safe” office job was the best decision she ever made, and what it's like to audition for Six in front of a room full of other queens going for the same role. We get into her current adventure in Operation Mincemeat, where she covers multiple roles and leans into the joy—and chaos—of live theater, from botched hat tosses to full-on breaking on stage. Gerianne also opens up about navigating performance anxiety, the nuanced realities of being a Latina performer in a typecasting-heavy industry, and the thrill of telling a story that honors forgotten heroes of history. Whether she's singing backup for a fellow principal, leading the charge as Monty, or making the audience laugh through an unexpected mishap, Gerianne embodies resilience, humor, and heart at every turn. Gerianne Pérez is an NYU Tisch-trained actor and singer whose career spans Broadway, national tours, and acclaimed off-Broadway productions. She made her Broadway debut in In Transit before joining Waitress and the national tour of Six: The Musical. She has also appeared in In the Heights, Grease, and Oratorio for Living Things, and is currently bringing her comedic chops to Operation Mincemeat on Broadway. This episode is powered by WelcomeToTimesSquare.com, the billboard where you can be a star for a day. Connect with Gerianne: Instagram: @gerianne.perez TikTok: @gerianne.perez Connect with The Theatre Podcast: Support the podcast on Patreon and watch video versions of the episodes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TheTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter & Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@theatre_podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook.com/OfficialTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TheTheatrePodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alan's personal Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@alanseales⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email me at feedback@thetheatrepodcast.com. I want to know what you think. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 144 Quack quack quack, the boys are back! In this episode Scott gets his Summers/Grey history and power set mixed up, and then becomes obsessed with the concept of a new character. Meanwhile, Corwin still does not believe the TVA will show up in Doomsday, then gets hit with mid-2000s memories. The books for June and July of 2025 are reviewed and they say goodbye to the end of Ziglar's run…kinda. In Past-O-Vision they travel back to 2006 and pull the band aid off and finally review the Deadpool Arc in Ultimate Spider-Man. In Monty's predictions, they revisit their predictions from 8 months ago, and make some new ones. And what is this?! Juggerduck ends the show with a contest! 0:03:28 Superman and Fantastic Four Spoilers 0:30:14 Deadpool/Wolverine (2025) #6 0:37:13 Deadpool/Wolverine (2025) #7 0:43:31 Deadpool Kills the Marvel Universe One Last Time (2025) #3 0:55:10 Deadpool Kills the Marvel Universe One Last Time (2025) #4 1:02:07 Deadpool (2024) #350 1:18:14 Wolverines and Deadpools (2025) #1 Past-O-Vision1 1:34:32 Ultimate Spider-Man (2000) #91 1:48:41 Ultimate Spider-Man (2000) #92 1:56:39 Monty's Predictions   [MwaP RSS] Subscribe [RSS All] Subscribe [Google Podcasts] Subscribe [Apple Podcasts] Subscribe Music by Jenki Girls of Los Angeles Email: HipsterDaken@gmail.com Website: http://www.EarthsMightiestPodcast.comFacebook Group: https://www.facebook.com/MercWithaPodcast/ Episodes #1-26 can be found @ Cultural Wormhole.com The Merc Report has now joined the EMP family of podcasts and has now become The Merc With a Podcast! -EXPLICIT CONTENT

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content